StockNews.com downgraded shares of SCYNEXIS (NASDAQ:SCYX – Free Report) from a hold rating to a sell rating in a research report released on Thursday.
SCYNEXIS Trading Up 8.6 %
SCYNEXIS stock opened at $0.93 on Thursday. SCYNEXIS has a 12-month low of $0.82 and a 12-month high of $3.07. The stock has a market cap of $35.37 million, a P/E ratio of -1.26 and a beta of 1.67. The company has a 50-day moving average price of $1.08 and a 200 day moving average price of $1.25.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The business had revenue of $0.98 million during the quarter.
Institutional Investors Weigh In On SCYNEXIS
SCYNEXIS Company Profile
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Read More
- Five stocks we like better than SCYNEXIS
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Using the MarketBeat Stock Split Calculator
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Sentiment Analysis: How it Works
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.